Shear stress and ROS-responsive biomimetic micelles for atherosclerosis via ROS consumption

Meili Shen1, Hongli Li2, Shunyu Yao1

  • 1Key Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun 130012, China.

Insights

This study introduces a novel nanomedicine system, SV MC@RBCs, that effectively treats atherosclerosis by simultaneously targeting reactive oxygen species (ROS) and plaque microenvironments. The system offers improved circulation and safety, addressing limitations of current therapies.

Area of Science:

  • Biomaterials Science
  • Nanomedicine
  • Cardiovascular Research

Background:

  • Reactive oxygen species (ROS) are key initiators of atherosclerosis, leading to endothelial dysfunction and plaque formation.
  • Current antithrombotic therapies using ROS-responsive systems inadequately eliminate excess ROS, hindering source treatment.
  • Nanoparticles face rapid clearance by the immune system, limiting their therapeutic efficacy in long-term circulation.

Purpose of the Study:

  • To develop an intelligent nanomedicine system that responds to both ROS and the shear stress microenvironment of atherosclerotic plaques.
  • To enhance atherosclerosis treatment by simultaneously depleting ROS and delivering therapeutic agents.
  • To improve nanoparticle circulation time and reduce immune system clearance.

Main Methods:

  • Development of simvastatin-loaded micelles (SV MC) composed of poly(glycidyl methacrylate)-polypropylene sulfide (PGED-PPS).
  • Assembly of SV MC with red blood cells (RBCs) via electrostatic adsorption to form SV MC@RBCs.
  • Evaluation of ROS-responsive micelle rupture and drug release, shear stress-induced desorption, immune evasion, and in vitro/in vivo therapeutic efficacy.

Main Results:

  • The PGED-PPS micelles reacted with ROS, leading to micelle rupture and drug release, while also depleting ROS levels.
  • SV MC@RBCs demonstrated responsiveness to shear stress, inducing micelle desorption from the RBC surface.
  • In vitro and in vivo studies confirmed effective atherosclerosis treatment, improved circulation, and excellent safety profile without bleeding risks.

Conclusions:

  • The SV MC@RBCs system offers a synergistic approach to atherosclerosis treatment by combining drug delivery with ROS scavenging.
  • Biomimetic design enhances circulation time and reduces immune clearance, overcoming limitations of conventional nanoparticles.
  • SV MC@RBCs represent a promising nanomedicine for treating ROS-related diseases, including atherosclerosis, with enhanced efficacy and safety.